Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Relapse in acute myeloid leukemia (AML) after chemotherapy reflects the persistence of resistant leukemia stem cells (LSCs). These cells have been described in the CD34 + CD38- cell fraction. Leukapheresis products were harvested in 123 patients in morphological complete remission and analyzed by multiparameter flow cytometry. The CD34 + CD38- cell population showed a prognostic impact on survival. Median event-free survival (EFS) was 8.2 months (3-year EFS: 29%) for those with a higher percentage of CD34 + CD38- versus 91.9 months (3-year EFS: 62%) for those with a lower percentage for the entire cohort. These differences were confirmed in patients undergoing autologous stem cell transplant, with median EFS of 7.3 months versus 91.1 months (3-year EFS: 31% vs. 70%). Higher proportions of CD34 + CD38- cells were associated with adverse cytogenetics and with earlier relapses. Higher percentages of CD34 + CD38- cells in apheresis products reflect inadequate in vivo purging and reliably distinguish samples enriched in LSCs from those involving mainly normal cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2014.927453 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expression of Oct3/4 isoforms and its association with the risk of relapse in acute lymphoblastic leukemia.
Biomed Rep
October 2025
Laboratory of Molecular Biomedicine, Faculty of Chemical and Biological Sciences, Autonomous University of Guerrero, Chilpancingo, Guerrero 39090, Mexico.
Oct3/4 is a transcription factor that maintains the stemness of both embryonic and adult stem cells. The Oct3/4 gene produces three isoforms: namely, Oct3/4A, Oct3/4B and Oct3/4B1. Increased Oct3/4 expression is associated with lower survival rates and chemoresistance in patients with cancer.
View Article and Find Full Text PDFThe Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.
Transplant Cell Ther
August 2025
Division of Blood and Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Stanford, CA. Electronic address:
Background: Autologous stem cell transplantation (ASCT) remains a standard component of frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). CD38 monoclonal antibodies (mAbs), such as daratumumab and isatuximab, have been incorporated into induction regimens and are associated with deeper responses. However, their impact on hematopoietic stem cell mobilization is unclear, particularly in real-world practice.
View Article and Find Full Text PDFLeukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
Bone Marrow Transplant
August 2025
Peking University People's Hospital & Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, China.
In this study, we explored the ability of leukemia stem cell (LSC)-based method and traditional multiparameter flow cytometry (MFC) assay to predict leukemia relapse after long-term follow-up. 360 AML patients who received allografts between July 2018 and November 2019 were prospectively enrolled. Patients with positive measurable residual disease (MRD) based on CD34CD38cocktail LSCs (≥0.
View Article and Find Full Text PDFAndrographolide promotes the ex vivo expansion of CD34+ hematopoietic stem cells derived from human umbilical cord blood.
Sci Rep
August 2025
Center of Excellence in Stem Research and Innovation, Thammasat University, Pathumthani, 12120, Thailand.
Umbilical cord blood (UCB) units are an alternative source of human hematopoietic stem cells (HSCs) for allogeneic stem cell transplants. A large quantity of HSCs is needed but the low number of accessible cells from UCB has been a significant limitation. Improving the ex vivo growth of HSCs while preserving their functioning is required.
View Article and Find Full Text PDFCD38 Endothelial Remodeling Defines Spatially Diverse Vasculopathy Programs in Rapidly Advancing Oral Inflammation.
bioRxiv
August 2025
Department of Oral and Craniofacial Molecular Biology, Philips Institute for Oral Health Research, Virginia Commonwealth University, Richmond, VA, USA.
Oral inflammatory diseases affect nearly half of the global population. Among them, newly defined peri-implantitis and high-grade periodontitis represent rapidly advancing inflammatory disease types, marked by relatively rapid tissue destruction. Despite their prevalence, the cell mechanisms and spatial architecture driving this severity remain poorly understood.
View Article and Find Full Text PDF